SKYE
What one share of Skye Bioscience holds
Pharmaceutical Preparations
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.
Skye Bioscience’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.27 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.98 |
| Cash and investments | $0.23 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$8.77 | $0.01 | −$5.75 | — | −$0.82 |
| 2023 | — | −$5.37 | $0.00 | −$1.99 | — | −$0.17 |
| 2024 | — | −$0.73 | $0.04 | −$0.74 | — | $2.20 |
| 2025 | — | −$1.41 | $0.00 | −$1.09 | — | $0.60 |